Glenmark Life Sciences Limited(IN:ALIVUS)
₹1,448.50-10.90 (-0.75%)
IN:ALIVUS
Glenmark Life Sciences Limited financials statements
₹1,448.50
At close:-10.90 (-0.75%)
Want to see IN:ALIVUS full AI Analyst Report?
Glenmark Life Sciences Limited (ALIVUS) Ratios
6 Followers
Glenmark Life Sciences Limited Ratios
IN:ALIVUS's free cash flow for Q2 2025 was ₹1.48B. For the 2025 fiscal year, IN:ALIVUS's free cash flow was decreased by ₹-1.13B and operating cash flow was ₹2.61B. See a summary of the company’s cash flow.
| Ratios | Mar 25 | Mar 24 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.21 | 4.97 | 4.60 | 1.15 | 0.67 |
| Quick Ratio | 3.85 | 3.53 | 3.25 | 0.73 | 0.38 |
| Cash Ratio | 0.00 | 0.15 | 1.33 | 0.09 | 0.00 |
| Solvency Ratio | 0.98 | 0.92 | 1.10 | 0.31 | 0.22 |
| Operating Cash Flow Ratio | 1.11 | 0.88 | 1.56 | 0.32 | 0.01 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -530.71 | 0.42 | 492.95 |
| Net Current Asset Value | ₹ 19.99B | ₹ 17.41B | ₹ 13.48B | ₹ 1.55B | ₹ -4.57B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.00 | 0.47 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.02 | 0.00 | 1.24 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.02 | 0.00 | 0.55 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.20 | 1.21 | 1.20 | 2.65 | 16.74 |
| Debt Service Coverage Ratio | 120.11 | 227.28 | 18.06 | 0.46 | 218.85 |
| Interest Coverage Ratio | 134.39 | 258.41 | 20.70 | 6.42 | 389.76 |
| Debt to Market Cap | 0.00 | 0.00 | -0.00 | 0.12 | 0.00 |
| Interest Debt Per Share | 5.06 | 4.82 | 2.62 | 94.65 | 0.05 |
| Net Debt to EBITDA | 0.07 | -0.02 | -0.81 | 1.38 | -0.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 44.57% | 32.20% | 50.88% | 51.97% | 55.41% |
| EBIT Margin | 29.65% | 27.68% | 27.92% | 29.63% | 28.79% |
| EBITDA Margin | 32.61% | 30.24% | 29.71% | 31.40% | 17.66% |
| Operating Profit Margin | 28.29% | 26.30% | 27.27% | 29.80% | 16.78% |
| Pretax Profit Margin | 29.44% | 27.58% | 26.61% | 24.98% | 28.74% |
| Net Profit Margin | 22.12% | 20.47% | 19.72% | 18.65% | 20.83% |
| Continuous Operations Profit Margin | 22.12% | 20.47% | 19.72% | 18.65% | 20.83% |
| Net Income Per EBT | 75.13% | 74.24% | 74.12% | 74.65% | 72.47% |
| EBT Per EBIT | 104.07% | 104.86% | 97.58% | 83.84% | 171.26% |
| Return on Assets (ROA) | 14.17% | 14.24% | 16.95% | 17.60% | 19.84% |
| Return on Equity (ROE) | 16.94% | 17.24% | 20.38% | 46.71% | 332.11% |
| Return on Capital Employed (ROCE) | 20.78% | 21.21% | 27.74% | 72.42% | 248.26% |
| Return on Invested Capital (ROIC) | 15.57% | 15.71% | 20.56% | 24.65% | 179.88% |
| Return on Tangible Assets | 14.28% | 14.32% | 17.02% | 17.67% | 19.92% |
| Earnings Yield | 4.72% | 3.83% | 7.77% | 4.36% | 3.19% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.38 | 2.35 | 3.15 | 2.76 | 3.04 |
| Payables Turnover | 3.80 | 4.12 | 3.56 | 4.07 | 3.34 |
| Inventory Turnover | 2.04 | 2.39 | 2.02 | 1.76 | 1.56 |
| Fixed Asset Turnover | 1.98 | 2.27 | 3.14 | 3.26 | 2.65 |
| Asset Turnover | 0.64 | 0.70 | 0.86 | 0.94 | 0.95 |
| Working Capital Turnover Ratio | 1.27 | 0.00 | 2.73 | 124.63 | -6.23 |
| Cash Conversion Cycle | 235.94 | 219.71 | 193.92 | 249.33 | 244.30 |
| Days of Sales Outstanding | 153.47 | 155.36 | 115.78 | 132.10 | 119.94 |
| Days of Inventory Outstanding | 178.56 | 152.97 | 180.68 | 206.96 | 233.55 |
| Days of Payables Outstanding | 96.09 | 88.63 | 102.54 | 89.73 | 109.19 |
| Operating Cycle | 332.03 | 308.34 | 296.46 | 339.05 | 353.49 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 46.13 | 33.58 | 50.85 | 36.00 | 0.84 |
| Free Cash Flow Per Share | 21.11 | 20.01 | 39.60 | 29.69 | 0.08 |
| Dividend Paid and CapEx Coverage Ratio | 1.54 | 2.48 | 2.29 | 5.71 | 1.11 |
| Capital Expenditure Coverage Ratio | 1.84 | 2.48 | 4.52 | 5.71 | 1.11 |
| Operating Cash Flow Coverage Ratio | 9.97 | 7.27 | 207.21 | 0.42 | 492.95 |
| Operating Cash Flow to Sales Ratio | 0.22 | 0.17 | 0.28 | 0.21 | 0.01 |
| Free Cash Flow Yield | 2.17% | 1.94% | 8.63% | 3.97% | 0.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 21.18 | 26.09 | 12.88 | 22.95 | 31.34 |
| Price-to-Sales (P/S) Ratio | 4.69 | 5.34 | 2.54 | 4.28 | 6.53 |
| Price-to-Book (P/B) Ratio | 3.59 | 4.50 | 2.62 | 10.72 | 104.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 46.15 | 51.66 | 11.59 | 25.21 | 8930.05 |
| Price-to-Operating Cash Flow Ratio | 21.12 | 30.79 | 9.02 | 20.79 | 885.93 |
| Price-to-Earnings Growth (PEG) Ratio | 1.32 | 0.00 | 1.39 | 1.87 | -0.00 |
| Enterprise Value Multiple | 14.44 | 17.64 | 7.74 | 15.01 | 36.95 |
| Enterprise Value | 120.12B | 126.53B | 48.83B | 88.86B | 91.69B |
| EV to EBITDA | 14.44 | 17.64 | 7.74 | 15.01 | 36.95 |
| EV to Sales | 4.71 | 5.33 | 2.30 | 4.71 | 6.53 |
| EV to Free Cash Flow | 46.36 | 51.60 | 10.49 | 27.76 | 8928.06 |
| EV to Operating Cash Flow | 21.22 | 30.76 | 8.17 | 22.90 | 885.73 |
| Tangible Book Value Per Share | 269.04 | 228.29 | 173.91 | 69.09 | 6.67 |
| Shareholders’ Equity Per Share | 271.48 | 229.92 | 174.80 | 69.82 | 7.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | 0.26 | 0.26 | 0.25 | 0.28 |
| Revenue Per Share | 207.91 | 193.57 | 180.66 | 174.87 | 114.67 |
| Net Income Per Share | 45.99 | 39.63 | 35.63 | 32.61 | 23.89 |
| Tax Burden | 0.75 | 0.74 | 0.74 | 0.75 | 0.72 |
| Interest Burden | 0.99 | 1.00 | 0.95 | 0.84 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| SG&A to Revenue | 0.16 | 0.02 | 0.00 | 0.00 | 0.01 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.00 | 0.63 | 1.06 | 0.82 | 0.05 |
Currency in INR

